EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

Regorafenib combined with immune checkpoint inhibitors versus regorafenib monotherapy as a late-line treatment for metastatic colorectal cancer: a single-center, retrospective cohort study

Can Chen, Xi Luo, Wenhua Tang, Haofei Geng, Julia Martínez-Pérez, Timothy Price, Lili Kang, Honglian Lu, Yanling Zhang

Journal of Gastrointestinal Oncology · 2024-08 · 15 (4) · 1497-1507

DOI: 10.21037/jgo-24-468 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Gastrointestinal Oncology, 2024-08. Verfasst von Can Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of the Army Medical University, Chongqing, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Colorectal cancer (CRC)immune checkpoint inhibitors (ICIs)metastaticprognosisregorafenib

Autor:innen und Institutionen

  • Department of Oncology, The First Affiliated Hospital of the Army Medical University, Chongqing, China.
  • Medical Oncology Department, University Hospital Virgen del Rocio, Seville, Spain.
  • Institute of Biomedicine of Seville (IBIS) (HUVR/University of Sevilla/CSIC), Seville, Spain.
  • Department of Medical Oncology, The Queen Elizabeth Hospital, Woodville, Australia.
  • University of Adelaide, School of Medicine, Adelaide, Australia.

Zitieren

APA

Chen, C., Luo, X., Tang, W., Geng, H., Martínez-Pérez, J., Price, T., Kang, L., Lu, H., & Zhang, Y. (2024). Regorafenib combined with immune checkpoint inhibitors versus regorafenib monotherapy as a late-line treatment for metastatic colorectal cancer: a single-center, retrospective cohort study. Journal of Gastrointestinal Oncology, 15(4), 1497-1507. https://doi.org/10.21037/jgo-24-468

Vancouver

Chen C, Luo X, Tang W, Geng H, Martínez-Pérez J, Price T, et al. Regorafenib combined with immune checkpoint inhibitors versus regorafenib monotherapy as a late-line treatment for metastatic colorectal cancer: a single-center, retrospective cohort study. Journal of Gastrointestinal Oncology. 2024;15(4):1497-1507. doi:10.21037/jgo-24-468

BibTeX
@article{Chen2024,
  author = {Chen, Can and Luo, Xi and Tang, Wenhua and Geng, Haofei and Martínez-Pérez, Julia and Price, Timothy and Kang, Lili and Lu, Honglian and Zhang, Yanling},
  title = {Regorafenib combined with immune checkpoint inhibitors versus regorafenib monotherapy as a late-line treatment for metastatic colorectal cancer: a single-center, retrospective cohort study},
  journal = {Journal of Gastrointestinal Oncology},
  year = {2024},
  volume = {15},
  number = {4},
  pages = {1497--1507},
  doi = {10.21037/jgo-24-468}
}
Kostenlos starten →